Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0214)
Name
Kainic acid
Synonyms
kainic acid; 487-79-6; Digenin; Digenic acid; Helminal; Kainate; L-alpha-Kainic acid; alpha-Kainic acid; Digensaeure; Kainsaeure; Acidum kainicum; Acide kainique; Acido kainico; C10H15NO4; 3-Pyrrolidineacetic acid, 2-carboxy-4-(1-methylethenyl)-, (2S,3S,4S)-; alpha- Kainic acid; (2S,3S,4S)-3-(Carboxymethyl)-4-(prop-1-en-2-yl)pyrrolidine-2-carboxylic acid; rac Kainic Acid; CHEMBL275040; SIV03811UC; DTXSID7040526; CHEBI:31746; 2-Carboxy-4-isopropenyl-3-pyrrolidineacetic acid; 3-Pyrrolidineacetic acid, 2-carboxy-4-isopropenyl-; NSC136038; NSC-759587; NCGC00024504-05; (3S,4R)-3-(carboxymethyl)-4-(prop-1-en-2-yl)-L-proline; 2-Carboxy-3-carboxymethyl-4-isopropenylpyrrolidine; NSC 136038; (2S-(2alpha,3beta,4beta))-2-carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid; DTXCID5020526; (3S,4S)-3-(carboxymethyl)-4-prop-1-en-2-yl-L-proline; (2S,3S,4S)-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid; Kainic acid [INN:JAN]; (2S,3S,4S)-3-(carboxymethyl)-4-prop-1-en-2-ylpyrrolidine-2-carboxylic acid; 3-(Carboxymethyl)-4-isopropenylproline; 4071-38-9; CAS-487-79-6; Acide kainique [INN-French]; Acido kainico [INN-Spanish]; Acidum kainicum [INN-Latin]; SR-01000075454; BRN 0086660; UNII-SIV03811UC; kainic-acid; NSC-136038; KAI; 1p1n; Kainic acid (synthetic); KAINIC ACID [MI]; Biomol-NT_000217; KAINIC ACID [INN]; UPCMLD-DP146; 3-Pyrrolidineacetic acid, 2-carboxy-4-(1-methylethenyl)-, (2S-(2alpha,3beta,4beta))-; Lopac0_000656; SCHEMBL15777; 4-22-00-01523 (Beilstein Handbook Reference); MLS001074661; KAINIC ACID [WHO-DD]; BPBio1_001306; (-)-(.alpha.)-Kainic Acid; UPCMLD-DP146:001; UPCMLD-DP146:002; HMS2233K05; HMS3262C13; HMS3266C11; HMS3411A21; HMS3675A21; HY-N2309; Tox21_110905; Tox21_500656; BDBM50002369; HB0355; Kainic Acid - CAS 487-79-6; AKOS024456995; Tox21_110905_1; CCG-204742; LP00656; SDCCGSBI-0050635.P002; 3-Pyrrolidineacetic acid, 2-carboxy-4-(1-methylethenyl)-, (2S-(2-alpha,3-beta,4-beta))-; NCGC00024504-02; NCGC00024504-03; NCGC00024504-04; NCGC00024504-06; NCGC00024504-07; NCGC00024504-08; NCGC00024504-09; NCGC00024504-15; NCGC00261341-01; SMR000471885; CS-0020451; EU-0100656; K 0250; Q390239; SR-01000597728; SR-01000075454-1; SR-01000075454-5; SR-01000075454-6; SR-01000075454-7; SR-01000597728-1; rel-(3R,4R)-3-(carboxymethyl)-4-isopropenyl-D-proline; 2S-CARBOXY-4S-(1-METHYLETHENYL)-3S-PYRROLDINEACETIC ACID; L-proline, 3-(carboxymethyl)-4-(1-methylethenyl)-, (3S,4S)-; (2S,3S,4S)-3-(Carboxymethyl)-4-Prop-1-En-2-yl-Pyrrolidine-2-Carboxylicacid; (2S-(2.ALPHA.,3.BETA.,4.BETA.))-2-CARBOXY-4-(1-METHYLETHENYL)-3-PYRROLIDINEACETIC ACID; InChI=1/C10H15NO4/c1-5(2)7-4-11-9(10(14)15)6(7)3-8(12)13/h6-7,9,11H,1,3-4H2,2H3,(H,12,13)(H,14,15)/t6-,7+,9-/m0/s

    Click to Show/Hide
Status
Investigative
Drug Type
Small molecular drug
Structure
Formula
C10H15NO4
IUPAC Name
(2S,3S,4S)-3-(carboxymethyl)-4-prop-1-en-2-ylpyrrolidine-2-carboxylic acid
Canonical SMILES
CC(=C)C1CNC(C1CC(=O)O)C(=O)O
InChI
InChI=1S/C10H15NO4/c1-5(2)7-4-11-9(10(14)15)6(7)3-8(12)13/h6-7,9,11H,1,3-4H2,2H3,(H,12,13)(H,14,15)/t6-,7+,9-/m0/s1
InChIKey
VLSMHEGGTFMBBZ-OOZYFLPDSA-N
PubChem CID
10255
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Status epilepticus ICD-11: 8A66
 Disease Info 
Pathway Response Ferroptosis hsa04216
Fatty acid metabolism hsa01212
Cell Process Cell ferroptosis
In Vitro Model SH-SY5Y cells Neuroblastoma Homo sapiens CVCL_0019
In Vivo Model
5-weeks-old kainate (KA)-induced BALB/c nude mice, a widely used epilepsy mouse model, were performed with intraperitoneal (i.p.) injection of KA (6 mg/kg). Pre-treatment 21 with antioxidant apigenin (60 mg/Kg, 2 days) or post-treatment with apigenin (60 mg/Kg, 1 day), mice were injected with KA (6 mg/kg) via intraperitoneal (i.p.) injection, and then HCP (0.5 mg/Kg) were injected by intravenous (i.v.) injection. In vivo and Ex vivo fluorescence images of relative ClO levels in mice brains 5, 15, 30, 45, and 60 min post injection of HCP were further performed by using the IVIS Spectrum imaging system (Nanjing University) with an excitation filter of 430 nm and the collection wavelength range is from 500-600 nm.

    Click to Show/Hide
Response regulation Apigenin can efficiently reduce the expression of intracellular MPO and increase the levels of GPX4 and SIRT1, thereby conferring neuroprotection through regulation of kainic acid (KA)-induced ferroptosis. And the level of Ac-p53 inside the brains treated with apigenin was down-regulated, suggesting that the p53-mediated ferroptosis pathway might be blocked. Overall, apigenin was screened and confirmed as an efficient lead compound for epilepsy prevention and treatment.
References
Ref 1 Epileptic brain fluorescent imaging reveals apigenin can relieve the myeloperoxidase-mediated oxidative stress and inhibit ferroptosis. Proc Natl Acad Sci U S A. 2020 May 12;117(19):10155-10164. doi: 10.1073/pnas.1917946117. Epub 2020 Apr 23.